Publish date:

Monday's Health Winners & Losers

Abbott Laboratories rises.

Abbott Laboratories

(ABT) - Get Report

was one of Monday's winners, a day after the company reported positive results from a clinical trial of its Xience drug-coated stent, clearing an important hurdle on the path to Food and Drug Administration approval. Abbott was recently adding $2.07, or 3.8%, to $55.93.

Meanwhile, shares of

TST Recommends

Boston Scientific

(BSX) - Get Report

slid more than 5% after the performance of Abbott's Xience stent was deemed superior to that of Boston Scientific's Taxus stent in a study. Lately, the stock was off 77 cents, or 5.1%, to $14.45.

Osiris Therapeutics

(OSIR) - Get Report

jumped after the company reported positive safety and efficacy data on Sunday from a phase I study of its adult stem-cell therapy, Provacel, in patients with heart disease. Osiris was higher by $2, or 11.2%, at $19.90.

Shares of

Merck

(MRK) - Get Report

were easing after the company announced a joint venture with

Schering-Plough

(SGP)

that will combine the cholesterol drug Lipitor with Zetia. Merck was losing 28 cents, or 0.6%, to $44.17.

Meanwhile, Schering-Plough was adding 52 cents, or 2.1%, to $25.14.

Pfizer

(PFE) - Get Report

, which holds the patent for Lipitor until 2010, was recently down 16 cents, or 0.6%, to $25.50.

Elsewhere,

Biosite

(BSTE)

soared 51.3% after

Beckman Coulter

(BEC)

said it will acquire the company.

Alexion Pharmaceuticals

(ALXN) - Get Report

was rising 10.6% to $44.30.

Among decliners,

CV Therapeutics

(CVTX)

dropped 20% to $6.86 on a downgrade by Deutsche Securities.

Express Scripts

(MDT) - Get Report

was sliding 1.8% to $82.16.

Medtronic

(MDT) - Get Report

was down 1.3% to $49.26.